Funding
i4L Innogrant for Biotherapeutics · Biotech

Eleum receives CHF100,000 for live-biotherapeutic development

The EPFL team will advance quality controls and preparation methods for its ulcerative colitis programme.

By RoundOS Funding desk

Eleum received a CHF100,000 i4L Innogrant for Biotherapeutics, EPFL announced on March 26, 2026. The team will develop quality controls and preparation protocols for a bacteria-based approach to ulcerative colitis.

Its research targets microbial pathways involved in the intestinal barrier.

Use of funds

Develop quality controls and preparation protocols for a live biotherapeutic.

Funding history

i4L Innogrant for Biotherapeutics · This roundCHF 100K

Sources

  1. EPFL startup grant award announcementactu.epfl.ch · Mar 26, 2026

Similar rounds

All Biotech rounds →
ALLOX

ALLOX combines high-throughput genetics, experimental biology and AI to find functional sites on proteins and develop targeted small-molecule medicines.

$10.5MSeed · Oct 29, 2026
Dren Bio

Dren Bio develops antibody therapies for cancer, autoimmune conditions and other serious diseases.

$350MPrivate financing · Oct 29, 2026
BioGeometry

BioGeometry develops generative AI models and experimental workflows for protein design, drug discovery and enzyme engineering.

UndisclosedSeries A+ · Oct 28, 2026
IntegriCulture

IntegriCulture develops cell-culture systems and production technology for cellular foods, cosmetics and other biological materials.

UndisclosedFunding round · Oct 28, 2026

Related